Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sildenafil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A known ✓ | O76074 | 20/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.82 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.82 |
| ▸ | PDE2A | O00408 | 1/20 | 0.82 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.82 |
| ▸ | PDE6D | O43924 | 1/20 | 0.82 |
| ▸ | PDE8A | O60658 | 1/20 | 0.82 |
| ▸ | PDE9A | O76083 | 1/20 | 0.82 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.82 |
| ▸ | HTR1A | P08908 | 1/20 | 0.82 |
| ▸ | PDE6A | P16499 | 1/20 | 0.82 |
| ▸ | PDE6G | P18545 | 1/20 | 0.82 |
| ▸ | PDE4A | P27815 | 1/20 | 0.82 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.82 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.82 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.82 |
| ▸ | PDE6B | P35913 | 1/20 | 0.82 |
| ▸ | PDE6C | P51160 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sildenafil SCHEMBL33982 | 1.00 | PDE5A (1.00) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL6509338 | 1.00 | PDE5A (1.00) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL405882 | 1.00 | PDE5A (1.00) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL405881 | 1.00 | PDE5A (1.00) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL28791531 | 0.99 | PDE5A (0.99) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL27980438 | 0.99 | PDE5A (0.99) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL6685385 | 0.99 | PDE5A (0.99) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL19410963 | 0.99 | PDE5A (0.99) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL17101160 | 0.99 | PDE5A (0.97) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL7374712 | 0.98 | PDE5A (0.96) | PDE5AABCC4PDE3BPDE3APDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3731870-B1 | LIQUID ORAL FORMULATIONS FOR PDE V INHIBITORS | LIQMEDS LTD (GB) | 2025-11-12 | — | — | EP | claimed |
| WO-2025106494-A1 | COMPOSITIONS AND METHODS FOR TREATING ERECTILE DYSFUNCTION AND MALE HYPOGONADISM | KONG YANPING (US) | 2025-05-22 | — | — | WO | claimed |
| EP-3090732-B1 | PHARMACEUTICAL COMPOSITION CONTAINING CLOMIPRAMINE AND PREPARATION METHOD THEREFOR | CTC BIO INC (KR) | 2024-07-24 | — | — | EP | claimed |
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | Triastek, Inc. (CN) | 2025-06-10 | — | — | US | disclosed |
| US-20250161252-A1 | COMPOUNDS FOR THE TREATMENT OF OBESITY AND METHODS OF USE THEREOF | THE GENERAL HOSPITAL CORPORATION | 2025-05-22 | — | — | US | disclosed |
| WO-2025106494-A1 | COMPOSITIONS AND METHODS FOR TREATING ERECTILE DYSFUNCTION AND MALE HYPOGONADISM | KONG YANPING (US) | 2025-05-22 | — | — | WO | disclosed |
| CN-119789862-A | Haptoglobin for use in the treatment or prevention of excessive erectile response or erectile dysfunction | 瑞士杰特贝林生物制品有限公司 | 2025-04-08 | — | — | CN | disclosed |
| EP-4512394-A2 | DOSAGE FORMS AND USE THEREOF | Triastek, Inc. (CN) | 2025-02-26 | — | — | EP | disclosed |
| US-20240408023-A1 | DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES | Triastek, Inc. (CN) | 2024-12-12 | — | — | US | disclosed |
| US-20240342094-A1 | COMPARTMENTED PHARMACEUTICAL DOSAGE FORMS | Triastek, Inc. (CN) | 2024-10-17 | — | — | US | disclosed |
| EP-3302442-B1 | DOSAGE FORMS AND USE THEREOF | TRIASTEK INC (CN) | 2024-10-16 | — | — | EP | disclosed |
| CN-118303626-A | Formula capable of improving human body functions and preparation method | 江西鼎高保健品有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20240011041-A1 | PHAGE COMPOSITIONS FOR PSEUDOMONAS COMPRISING CRISPR-CAS SYSTEMS AND METHODS OF USE THEREOF | Locus Biosciences, Inc. | 2024-01-11 | — | — | US | disclosed |
| EP-4240165-A1 | PHAGE COMPOSITIONS FOR PSEUDOMONAS COMPRISING CRISPR-CAS SYSTEMS AND METHODS OF USE THEREOF | Locus Biosciences, Inc. (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-3299010-B1 | ORAL DOSAGE FORM | LTS LOHMANN THERAPIE SYSTEME AG (DE) | 2022-11-09 | — | — | EP | disclosed |
| EP-4082541-A1 | COMPOUNDS FOR THE TREATMENT OF OBESITY AND METHODS OF USE THEREOF | The Children's Medical Center Corporation (US) | 2022-11-02 | — | — | EP | disclosed |
| WO-2022098916-A1 | PHAGE COMPOSITIONS FOR PSEUDOMONAS COMPRISING CRISPR-CAS SYSTEMS AND METHODS OF USE THEREOF | Locus Biosciences, Inc. (US) | 2022-05-12 | — | — | WO | disclosed |
| EP-3434268-B1 | COMPOUNDS FOR THE TREATMENT OF OBESITY AND METHODS OF USE THEREOF | CHILDRENS MEDICAL CT CORP (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3981392-A1 | CONTROLLED RELEASE DOSAGE FORM | Triastek, Inc. (CN) | 2022-04-13 | — | — | EP | disclosed |
| US-11278499-B2 | Oral drug dosage form comprising various release profiles | Triastek, Inc. (CN) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | CYP2D6, CYP3A5, CYP3A7 | PDE5A 1399/4885ABCC4 63/4885PDE3B 2158/4885 |
| US-11278499-B2 | Oral drug dosage form comprising various release profiles | CYP2D6, CYP3A7, CYP3A5 | PDE5A 633/4885ABCC4 84/4885PDE3B 867/4885 |
| US-20240342094-A1 | COMPARTMENTED PHARMACEUTICAL DOSAGE FORMS | CYP2D6, CYP3A5, CYP2F1 | PDE5A 785/4885ABCC4 433/4885PDE3B 1401/4885 |
| US-20250161252-A1 | COMPOUNDS FOR THE TREATMENT OF OBESITY AND METHODS OF USE THEREOF | GPR119, ADIPOR1, FABP4 | PDE5A 549/4885ABCC4 2528/4885PDE3B 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.